Analysts See 435% Upside in This Tiny Biotech Stock

Biotech investing is often a high-risk, high-reward game—but once in a while, a company emerges with potential that even seasoned investors can’t ignore. One such contender is Iovance Biotherapeutics Inc (NASDAQ: IOVA), a small-cap cancer immunotherapy company that has gained attention after FDA approval, promising clinical data, and strategic insider and institutional moves.  Could Iovance…

IOVA Tiny Bioteech Stock to buy